Nasdaq:US$19.90 (+0.00) | HKEX:HK$31.35 (-0.05) | AIM:£3.13 (-0.02)
2000
FOUNDED
HCM
NASDAQ &
LONDON AIM
13
HKEX
13
IN-HOUSE DISCOVERED
CLINICAL STAGE CANCER
DRUG CANDIDATES
3
APPROVED & MARKETED
PRODUCTS IN CHINA
1
APPROVED & MARKETED
PRODUCT IN THE U.S.
~40
CLINICAL TRIALS WORLDWIDE
INCLUDING 13 REGISTRATION STUDIES
5,000
PERSONNEL ACROSS
THE GROUP

OUR SCIENCE

Our core research and development philosophy is to take a holistic approach and treat cancer and immunological diseases through multiple modalities and mechanisms. We have taken a science-focused approach to develop highly selective, potent and well-tolerated cancer therapies that are deliberately engineered to improve drug exposure and reduce off-target toxicities.

R&D Philosophy Pipeline Products

Events, Circulars And Forms


Citi's 2024 Macro & Pan-Asia Regional Conference, Singapore 2024-05-30 - 2024-05-31
Goldman Sachs 45th Annual Global Healthcare Conference, Miami 2024-06-10
Corporate Presentation for Investors 2024-05-06